Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp160 (gp160)
- Target
- gp160
- Molecular classification
- Glycoprotein, Viral envelope protein, Precursor protein
01
Overview
The HIV-1 envelope glycoprotein gp160 is a precursor polyprotein essential for viral entry into host cells. It is cleaved into gp120 and gp41, which mediate receptor binding and membrane fusion, respectively. gp160 is a major target for vaccine development and therapeutic intervention due to its critical role in the viral lifecycle.
- Other names
- HIV-1 gp160Env gp160gp160 precursor polyprotein
02
Mechanism of action
gp120 binding to CD4, gp120 binding to CCR5 or CXCR4, gp41-mediated membrane fusion, inhibition of gp41
03
Biological functions
Viral entryReceptor bindingMembrane fusionOligomerizationViral assembly
04
Disease associations
HIV infectionAIDS pathogenesis
05
Safety considerations
High sequence variabilityGlycosylation maskingImmune evasionDevelopment of resistance to entry inhibitorsChallenges in eliciting broadly neutralizing antibodies through vaccination
06
Interacting drugs
Entry inhibitors (e.g., Maraviroc, Enfuvirtide)
1 more in the full profile.
07
Biomarkers
gp120 V1-V5 loop sequences (for tropism prediction)gp160/gp120 antibody titers (for vaccine efficacy)
Beyond the preview
Go deeper on Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp160 (gp160).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp160 (gp160).